NTRK-fused gliomas in our cohort demonstrated concurrent aberrations involving CDKN2A/2B, TERT promoter, TP53, PTEN, EGFR, ATRX, RB1, IDH1, polysomy 7, ROS1, PIK3CA, NF1, and MDM4. The frequency of these genetic aberrations in NTRK-fused gliomas increased with patient age cohort and seemed to correlate with histological grade in the pediatric and adult cohorts. The gene discussed is CDKN2A; the disease is central nervous system cancer.